PMN
NASDAQProMIS Neurosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks44-100%
2025-12-282026-06-21
Mix2890d
- SEC Filings11(39%)
- Insider10(36%)
- Other5(18%)
- Earnings2(7%)
Latest news
25 items- SECSEC Form S-8 filed by ProMIS Neurosciences Inc.S-8 - ProMIS Neurosciences Inc. (0001374339) (Filer)
- PRProMIS Neurosciences to Participate in Upcoming Conferences in JuneCAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings. Conference details below:Jefferies Global Healthcare Conference, June 2-4, 2026Location: New York, NYPresentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ETWebcast link: Click here.Virtual Alzheimer's R&D Day, organized by Wolfe Research, June 4, 2026Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.
- INSIDERSEC Form 4 filed by Director Wyman William W4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Williams Eugene4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Warma Neil K4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Shafmaster Madge K.4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Cashman Neil4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer Milbury Max A.4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Mandel-Brehm Josh4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Kaplan Johanne4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- INSIDERSEC Form 4 filed by Director Alex Slanix Paul4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- SECProMIS Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
- SECSEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
- SECSEC Form 10-Q filed by ProMIS Neurosciences Inc.10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)
- PRProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsCompany closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. The planned interim analysis is expected to include a qualitative assessment of aggregated safety data, including amyloid-related imaging abnormalities (ARIA) incidence, as well as key biomarker trends acros
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProMIS Neurosciences Inc.SCHEDULE 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)
- INSIDERDirector Kirwin Patrick D. bought $45,320 worth of shares (4,000 units at $11.33) (SEC Form 4)4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)
- SECSEC Form DEFA14A filed by ProMIS Neurosciences Inc.DEFA14A - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form DEF 14A filed by ProMIS Neurosciences Inc.DEF 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form SCHEDULE 13G filed by ProMIS Neurosciences Inc.SCHEDULE 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)
- SECSEC Form EFFECT filed by ProMIS Neurosciences Inc.EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form EFFECT filed by ProMIS Neurosciences Inc.EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)
- SECSEC Form S-3 filed by ProMIS Neurosciences Inc.S-3 - ProMIS Neurosciences Inc. (0001374339) (Filer)
PMN FAQ
5 questionsWhat does ProMIS Neurosciences Inc. do?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA...Where does PMN stock trade?
ProMIS Neurosciences Inc. (PMN) is listed on NASDAQ.What sector and industry is PMN in?
ProMIS Neurosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to PMN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PMN side-by-side with any of them on Quantisnow.How can I track PMN on Quantisnow?
Quantisnow aggregates ProMIS Neurosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PMN to receive live email and push alerts on every new disclosure.